Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q2 2025 value amounting to $366000.0.

  • Verrica Pharmaceuticals' Other Accumulated Expenses rose 2159.47% to $366000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $366000.0, marking a year-over-year increase of 2159.47%. This contributed to the annual value of $105000.0 for FY2024, which is 5696.72% down from last year.
  • As of Q2 2025, Verrica Pharmaceuticals' Other Accumulated Expenses stood at $366000.0, which was up 2159.47% from $166000.0 recorded in Q1 2025.
  • Verrica Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $428000.0 for Q3 2024, and its period low was $105000.0 during Q4 2024.
  • Over the past 3 years, Verrica Pharmaceuticals' median Other Accumulated Expenses value was $291500.0 (recorded in 2023), while the average stood at $276625.0.
  • The largest annual percentage gain for Verrica Pharmaceuticals' Other Accumulated Expenses in the last 5 years was 5177.3% (2024), contrasted with its biggest fall of 5696.72% (2024).
  • Verrica Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $244000.0 in 2023, then plummeted by 56.97% to $105000.0 in 2024, then soared by 248.57% to $366000.0 in 2025.
  • Its Other Accumulated Expenses stands at $366000.0 for Q2 2025, versus $166000.0 for Q1 2025 and $105000.0 for Q4 2024.